Abstract: A computing platform is configured to: (i) receive an indication of a given investigator decision of whether or not given transaction activity is suspicious; (ii) load source data for use in predicting whether the given transaction activity is suspicious; (iii) based on the loaded source data, prepare feature data for an AI model framework that is configured to predict whether transaction activity underlying an investigator decision is suspicious; (iv) input the feature data into the AI model framework and thereby cause the AI model framework to generate and output a prediction of whether or not the given transaction activity is suspicious; (v) determine that there is a mismatch between (a) the given investigator decision and (b) the prediction of whether or not the given transaction activity is suspicious; and (vi) based on the determination, flag the given investigator decision for quality review.

Abstract: Platinum-containing compounds for the treatment of disease, such as, for example, cancer, are provided herein. Specifically, platinum Pt(IV) complexes with a substituted 2,2?-bipyridine ring structure are provided, as are methods for using the complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Platinum-containing compounds for the treatment of disease, such as, for example, cancer, are provided herein. Specifically, platinum Pt(IV) complexes with a substituted 2,2?-bipyridine ring structure are provided, as are methods for using the complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of: a) identifying a prospective patient having cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells; and b) administering a cisplatin derivative to the prospective patient so that the cisplatin derivative will contact the cancer cells; wherein the cisplatin derivative is a 4,4?-bis[RO]-2,2?-bipyridine)PtCl2 where, R is selected from the group consisting of —(CH2)nCH3 where n=2, 3, 4 or 5, and —(CH2)n[O(CH2)m]yO(CH2)zCH3 where n=2, m=2, y=2, z=1. A novel synthetic process for the manufacture of these compounds (and their analogs) is also provided.

Abstract: A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of: a) identifying a prospective patient having cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells; and b) administering a cisplatin derivative to the prospective patient so that the cisplatin derivative will contact the cancer cells; wherein the cisplatin derivative is a 4,4?-bis[RO]-2,2?-bipyridine)PtCl2 where, R is selected from the group consisting of —(CH2)nCH3 where n=2, 3, 4 or 5, and —(CH2)n[O(CH2)m]yO(CH2)zCH3 where n=2, m=2, y=2, z=1. A novel synthetic process for the manufacture of these compounds (and their analogs) is also provided.